论文部分内容阅读
来自美国克利夫兰临床中心的Lincoff教授等进行了一项名为AleCardio的研究,旨在研究标准方案治疗基础上增加Aleglitazar(一种强有力的过氧化物酶体增殖物激活受体PPARα/γ双激动剂)是否减少近期发生急性冠脉综合征(ACS)的2型糖尿病患者的心血管死亡及发病风险。该研究共纳入7226名在2010年2月至2012年5月期间发生ACS(心肌梗死或不稳定型心绞痛)的2型糖尿病患者。患者按1:1随机分为Aleglitazar组(150μg,1/d)或
Professor Lincoff from the Cleveland Clinic Center of the United States conducted a study called AleCardio to study the standard regimen based on the addition of Aleglitazar, a potent PPARα / γ dual agonist of peroxisome proliferator-activated receptor ) Reduces cardiovascular mortality and morbidity in patients with type 2 diabetes who have had recent acute coronary syndromes (ACS). The study enrolled 7,226 patients with type 2 diabetes who developed ACS (myocardial infarction or unstable angina) between February 2010 and May 2012. Patients were randomly assigned to Aleglitazar group (150 μg, 1 / d) or 1: 1